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A B S T R A C T
Recent progress in nanobiotechnology has attracted interest to a biomedical application of the carbon nanos-
tructure C60 fullerene since it possesses a unique structure and versatile biological activity. C60 fullerene po-
tential application in the frame of cancer photodynamic therapy (PDT) relies on rapid development of new light
sources as well as on better understanding of the fullerene interaction with cells.
The aim of this study was to analyze C60 fullerene eﬀects on human leukemic cells (CCRF-CEM) in combi-
nation with high power single chip light-emitting diodes (LEDs) light irradiation of diﬀerent wavelengths: ul-
traviolet (UV, 365 nm), violet (405 nm), green (515 nm) and red (632 nm). The time-dependent accumulation of
fullerene C60 in CCRF-CEM cells up to 250 ng/106 cells at 24 h with predominant localization within mi-
tochondria was demonstrated with immunocytochemical staining and liquid chromatography mass spectro-
metry. In a cell viability assay we studied photoexcitation of the accumulated C60 nanostructures with ultraviolet
or violet LEDs and could prove that signiﬁcant phototoxic eﬀects did arise. A less pronounced C60 fullerene
phototoxic eﬀect was observed after irradiation with green, and no eﬀect was detected with red light. A C60
fullerene photoactivation with violet light induced substantial ROS generation and apoptotic cell death, con-
ﬁrmed by caspase3/7 activation and plasma membrane phosphatidylserine externalization. Our work proved C60
fullerene ability to induce apoptosis of leukemic cells after photoexcitation with high power single chip 405 nm
LED as a light source. This underlined the potential for application of C60 nanostructure as a photosensitizer for
anticancer therapy.
1. Introduction
Photodynamic therapy is a non-surgical approach aimed on the
selective elimination of cancer cells. The main idea of PDT is to com-
bine two non-toxic components – photosensitizing molecule and visible
light – which in the presence of oxygen gain a pronounced toxicity
[1–3]. Anticancer PDT eﬀects are realized directly through the induc-
tion of cancer cell death and/or indirectly when damage of the vascular
system and activation of the immune response are provoked [4,5].
Rapid development of endoscopic ﬁber optic devices [6,7] allows to test
PDT in treatment not only for skin malignacies, but for brain, lung,
esophagus, colon, pancreas, liver, bile duct, breast, bladder, prostate
and neck cancers as well [1,4,8].
Over the past decade, the application of nanoparticulate agents has
been established both in pharmaceutical research and in clinical set-
tings [4,9]. The constantly increasing interest in novel nanotechnology
platforms for biomedical applications stimulated the investigation of
carbon nanomaterials, including fullerenes and their most prominent
representative – C60 fullerene [10]. Pristine non-modiﬁed C60 fullerene
is a lipophilic, spheroidal shaped and symmetrical molecule with
0.72 nm in diameter [11,12]. Due to the speciﬁc packing of atoms in
penta- and hexagon units the surface of C60 is three times smaller than
expected for biological molecules with the same molecular weight of
720 Da. The unusual structure of C60 fullerene determines its unique
physicochemical properties and biological activity [9,11–14].
Today considerable attention is devoted to C60 fullerene as potential
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regulator of oxidative balance in biological systems. Since a C60 mole-
cule consists entirely of sp2-hybridized carbon atoms [14], it is able to
generate reactive oxygen species (ROS) after UV–vis light irradiation
with a quantum yield of 1.0 [15]. C60 fullerene advantages compared to
conventional photosensitizing molecules are the higher photostability
and lesser photobleaching [2]. There are two ways of ROS production
by photoexcited C60: by energy (type I) or electron (type II) transfer
from photoexcited C60 to oxygen (Fig. 1) [2,15–19]. The produced re-
active oxygen species are excellent oxidizing agents that react with a
wide range of biological targets. Oxidative stress, which occurs when
ROS generation overwhelms the cell antioxidant defense system can
lead to cell death by apoptosis [16–18]. Mitochondria have been found
to be an important subcellular target for many photosensitizing drugs
due to its role in apoptosis induction [3,17].
C60 fullerene-mediated PDT eﬃciency in vitro and in vivo was
shown to a large extent with its hydrophilic derivatives hydroxy-
[14,17,20], carboxy- [16], PEG [10,12,17] -C60 and C60 with various
organic substitutes [15,18,20–23]. Functionalization of C60 improves
its water solubility and increases its biocompatibility by decreasing the
aggregate size [14], but on the other hand, inhibits its interaction with
cellular lipid membranes and changes the pattern of cellular uptake
[14,18,19,22,23]. C60 diﬀuses through bilayered membrane from six
[22] to nine [24] orders of magnitude faster as compared with its hy-
drophilic derivatives, which interact with polar groups on the mem-
brane surface instead of entering the cell. Higher lipophilicity promotes
diﬀusion of pharmaceutical agents across the plasma membrane and
further relocation to other cellular membranes, thus facilitating in-
tracellular uptake [17]. Hydrophobic drugs are shown to attack the
cancer cells mainly by direct interactions, weather hydrophilic agents
act indirectly by damaging blood vessels [18]. Moreover, the presence
of functional groups on C60 fullerene surface decreases the quantum
yield of singlet oxygen production after molecule photoexcitation
[15,16]. So, the cellular uptake and further biological eﬀects of pristine
C60 and its derivatives could be diﬀerent. Pristine C60 fullerene may be
applied in PTD in the form of liposome-based delivery systems
[2,8,16,25,26] or water colloidal C60 solutions [16,27–30]. Previously,
a negligible toxicity of pristine C60 stable colloid solution [30] against
normal cells was shown [29,30]. At the same time a pronounced
proapoptotic eﬀect was detected in leukemic cells treated with pristine
C60 fullerene and irradiated with UV/Vis light in the range of
320–600 nm [11,27,31]. These data indicate the potential of C60 as an
eﬀective photosensitizer in cancer therapy.
The use of high power single chip light-emitting diodes is expected
to promote PDT application, since they have a higher portability and
extremely lower cost, compromising the eﬃciency [32,33] of lasers as
the classical PDT light sources. LED-based equipment has a high po-
tential to simplify PDT's technical part and to reduce costs [34]. In this
paper, we report ﬁrst data concerning the pristine C60 fullerene accu-
mulation and localization inside human leukemic cells and its photo-
toxic eﬀects potentially induced by UV, violet, green and red high
power single chip LEDs light irradiation.
2. Materials and methods
2.1. Chemicals
RPMI 1640 liquid medium, phosphate buﬀered saline (PBS), Fetal
Bovine Serum (FBS), Penicillin/Streptomycin and L-glutamin were ob-
tained from Biochrom (Berlin, Germany). Poly-D-lysine hydrobromide,
Triton X100, Bovine Serum Albumin (BSA), 4′,6-Diamidine-2′-pheny-
lindole dihydrochloride (DAPI), glycerol, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) and sucrose were obtained
from Sigma-Aldrich Co. (St-Louis, USA). Dimethylsulfoxide (DMSO),
trypan blue, paraformaldehyde, toluene, methanol, 2-isopropanol,
acetonitrile, tris(hydroxymethyl)aminomethane (Tris) and ethylene
glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) from
Carl Roth GmbH +Co. KG (Karlsruhe, Germany) were used. 3-(N-
morpholino)propanesulphonic acid (MOPS) was purchased from ICN
Biomedicals Inc. (Ohio, USA).
2.2. C60 fullerene synthesis
The pristine C60 fullerene aqueous colloid solution was prepared as
described in [28] by C60 fullerene transfer from toluene to water using
continuous ultrasound sonication. Obtained C60 colloid solution was
characterized by high C60 fullerene concentration (2×10-4 М, purity
99%), stability and homogeneity.
2.3. Spectrophotometric analysis
Samples (100 μl of C60 colloid solution) were placed into a 96-well
plate Sarstedt (Nümbrecht, Germany), C60 absorbance spectrum was
measured with the multimode microplate spectrometer Tecan inﬁnite
M200 PRO (Grödig, Austria) at the following parameters: wavelength
range 200–900 nm, wavelength step size: 2 nm, number of ﬂashes per
well: 10.
2.4. Cell culture
The human cancer cell line of leucosis origin – CCRF-CEM (ACC
240) – was purchased from the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures. Cells were maintained
in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum, 1%
Penicillin/Streptomycin and 2mM Glutamine, using 25 cm2 ﬂasks at a
37 °C with 5% CO2 in a humidiﬁed incubator Binder (Tuttlingen,
Germany). The number of viable cells was counted using 0.1% trypan
blue staining and a Roche Cedex XS Analyzer (Basel, Switzerland).
2.5. Immunoﬂuorescence staining
CCRF-CEM cells (2× 105/ml) were seeded in 6-well plates
(Sarstedt, Nümbrecht, Germany) on cover slips (Carl Roth, Karlsruhe,
Germany), previously coated with poly-D-Lysine, and incubated for
24 h. Cells were treated with 20 µM C60 colloid solution for further 24 h.
Then cells were washed with PBS, stained with MitoTracker Orange FM
(Invitrogen Molecular Probes, Carlsbad, USA) for 30min at 37 °C and
then ﬁxed with 4% paraformaldehyde for 15min at room temperature
(RT) in the dark. After washing with PBS, cells were permeabilized with
Fig. 1. Schematic mechanism of C60 fullerene photodynamic cancer therapy.
An absorbed photon excites C60 fullerene to the ﬁrst excited singlet state S1, that
relaxes to the more long lived triplet state T1. The C60 triplet interacts with
oxygen either through type I or type II, resulting in the intensiﬁcation of re-
active oxygen species generation and induction of apoptotic cell death.
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0.2% Triton X100 for 10min at RT and washed again with PBS.
Blocking was performed using 10% BSA for 20min with following
washing in PBS. The primary monoclonal antibody IgG (developed in
mouse) against C60 fullerene conjugated to thyroglobulin of bovine
origin (dilution ratio of 1:30 in PBS/1.5%BSA, 1–10F-A8 Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) was added to the CCRF-CEM
cells and incubated overnight at 4 °C in a humidiﬁed chamber. Then
CCRF-CEM cells were incubated for 3 h at RT with a FITC-labeled
polyclonal antibody against mouse IgG developed in rabbit (dilution
ratio of 1:200 in PBS/1.5%BSA, F7506 Sigma-Aldrich Co., St-Louis,
USA). Slides were washed between each step in three shifts of PBS for
15min each. The coverslips were rinsed with dH2O, incubated with
nucleus staining antifade solution (0.6 µM DAPI, 90mM p-
Phenylenediamine in glycerol/PBS) for 2 h in the dark and sealed with
slides. CCRF-CEM cells were observed using a Fluorescence Microscope
Keyence BZ-9000 BIOREVO (Osaka, Japan) equipped with blue (λex
377 nm, λem 447 nm), green (λex 472 nm, λem 520 nm) and red (λex
543 nm, λem 593 nm) ﬁlters with the acquisition software Keyence BZ-II
Viewer (Osaka, Japan). The merged images and single cell ﬂuorescence
intensity proﬁles were processed with the Keyence BZ-II Analyzer
software (Osaka, Japan).
2.6. High performance liquid chromatography-electro spray ionization-mass
spectrometry (HPLC-ESI-MS)
The liquid chromatography separation and mass spectrometric de-
tection were achieved by employing the Nexera HPLC system coupled
to the LCMS-8040 Tandem Quadrupole Mass Spectrometer, equipped
with an ESI source (Shimadzu, Kyoto, Japan). Chromatographic se-
paration was performed using the column Eclipse XDV-C8 150mm×
4,6mm, 5 µm (Agilent, Santa Clara, USA). Optimized HPLS-ESI-MS
conditions described in [35]. For data processing the software LabSo-
lutions LCMS (Shimadzu, Kyoto, Japan) was used.
2.7. C60 fullerene extraction
CCRF-CEM cells (2× 105/ml) were seeded in 6-well plate Sarstedt
(Nümbrecht, Germany). After 24 h cells were incubated for 0–48 h in
the presence of 20 µM C60, washed with PBS three times and transferred
to the dH20. The freeze-thawing cycle was repeated three times. The
probes were dried at 80 °C under reduced pressure. Toluene/2-propanol
(6:1, v/v) was added in the ﬁnal volume 0.5ml, the mixture was so-
nicated for 1 h and centrifuged (70min, 20238g). The toluene layer was
analyzed with HPLC-ESI-MS.
2.8. Isolation of mitochondria
CCRF-CEM cells were incubated for 24 h in the presence of 20 µM
C60 and the mitochondria fraction was isolated accordingly to [36].
Brieﬂy, cell suspension (5×106/4ml) was centrifuged at 600g at 4 °C
for 10min, cells were resuspended in 3ml of ice cold isolation buﬀer
(IB: 0.01M Tris-MOPS, 1mM EGTA/Tris, 0.2 M sucrose, pH 7.4) and
homogenized in the teﬂon-glass potter on ice. The homogenate was
centrifuged at 600g at 4 °C for 10min. The collected supernatant (S1)
was centrifuged at 7000g at 4 °C for 10min. The pellet (P2) was re-
suspended in 200 μl ice-cold IB and centrifuged at 7000g at 4 °C for
10min. The mitochondrial fraction obtained in pellet (P3) was used for
extraction of C60 fullerene as well as for measurements of protein
concentration [37] and succinate-reductase activity as mitochondrial
marker [38]. The data concerning mitochondrial purity test available in
[35].
2.9. Photodynamic therapy in vitro and cell viability assay
For cell viability assay, 104 cells/well were cultured in 96-well cell
culture plates (Sarstedt, Nümbrecht, Germany) at for 24 h and then
incubated for 24 h with 20 µM C60 and washed with PBS. Light irra-
diation was applied at the following wavelengths: UV – 365 nm Nichia
SMD LED UV NCSU275, 140.6 mW/cm2 (LUMITRONIX LED-Technik
GmbH, Hechingen, Germany); violet – 405 nm high power single chip
LED VL400-EMITTER, 108.3 mW/cm2; green – 515 nm high power
single chip LED APG2C1–515, 50.9mW/cm2; red – 650 nm, ELD-650-
523, 5.1 mW/cm2 (Roithner Lasertechnik GmbH, Vienna, Austria); red
– 632 nm helium-neon 30mW laser, 90mW/cm2 (Melles Griot, New
York, USA). The light ﬂuence was used in the range of 1–8 J/cm2 for
UV, 5–20 J/cm2 for violet and green light and 1–80 J/cm2 for red light.
PBS was replaced with fresh medium immediately after irradiation.
Control cells were incubated without exposure to fullerene treatment or
light irradiation. After 24 h incubation cell viability was determined
with MTT reduction assay. 10 μl of MTT solution (5mg/ml in PBS) was
added to each well and cells were incubated for 2 h at 37 °C. The culture
medium was then replaced with 100 μl of DMSO, diformazan formation
was determined by measuring absorption at 570 nm with a microplate
reader Tecan Inﬁnite M200 Pro (Männedorf, Switzerland).
2.10. Intracellular ROS-generation
To determine ROS production 2,7-dichloroﬂuorescin diacetate
(DCFH-DA) (Sigma-Aldrich Co., St-Louis, USA) was applied. A 5mM
stock solution of DCFH-DA was prepared in DMSO, stored at −20 °C
and diluted with PBS immediately before use. 104 cells were incubated
in RPMI with 20 µM C60 for 24 h, irradiated (10 J/cm2 405 nm LED) as
indicated above, and washed once with PBS at 1 h and 3 h of further
incubation. 5 µM DCF-DA was added and the ﬂuorescence (λex 488 nm,
λem 520 nm) was recorded every 5min during 50min with the micro-
plate reader Tecan Inﬁnite M200 Pro (Männedorf, Switzerland). After
60min incubation ﬂuorescent images of cells were obtained with the
Fluorescence Microscope Keyence BZ-9000 BIOREVO (Germany),
equipped with a green ﬁlter (λex 472 nm, λem 520 nm).
2.11. Caspase 3/7 activity
The CCRF-CEM cells were seeded into 96-well plates (104 cells/
well) and incubated for 24 h. The cells were treated with 20 µM C60 for
24 h and irradiated (405 nm, 10 J/cm2) irradiation as described above.
Activity of caspases 3/7 was determined during 6 h period after light
exposure using the Promega Caspase-Glo® 3/7 Activity assay kit
(Madison, USA) according to the manufacturer's instructions. Brieﬂy,
the plates were removed from the incubator and allowed to equilibrate
to RT for 30min. After treatment, an equal volume of Caspase-Glo 3/7
reagent was added followed by gentle mixing with a plate shaker at
300 rpm for 1min. The plate was then incubated at RT for 2 h. The
luminescence of each sample was measured with the microplate reader
Tecan Inﬁnite M200 Pro (Männedorf, Switzerland).
2.12. Flow cytometry analysis
CCRF-CEM cells were seeded onto 6-well plates at a cell density of
2× 105 cells/well in 2ml of culture medium, incubated for 24 h, than
treated with 20 µM C60 for 24 h and irradiated with 405 nm LED as
described above. At 6 and 24 h incubation period the cells were har-
vested. Apoptosis was detected by Annexin V-ﬂuorescein iso-
thiocyanate/propidium iodide (Annexin V-FITC/PI) apoptosis detection
kit (eBioscience™, San Diego, USA) according to the manufacturer's
instructions. Brieﬂy, cells were harvested and washed with Binding
buﬀer. After addition of FITC-conjugated Annexin V cells were in-
cubated for 15min at RT in dark. Cells were washed with Binding
buﬀer and at 10min after propidium iodide addition were analyzed
with the ﬂow cytometer BD FACSJazz™ (Singapore). A minimum of
20,000 cells per sample were acquired and analyzed with the BD FACS™
software (Singapore).
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2.13. Statistical analysis
All experiments were carried out with a minimum of four replicates.
Data analysis was performed with the use of the GraphPad Prism 7
(GraphPad Software Inc., USA). Paired Student's t-tests were performed.
Diﬀerences values p < 0.05 were considered to be signiﬁcant.
3. Results and discussion
3.1. C60 fullerene uptake by leukemic cells and its intracellular distribution
The ﬁrst requirement for any photosensitizing agent is an extensive
penetration into the cancer cells since otherwise ROS generation is not
suﬃcient to induce cell death. Eﬀective cellular uptake of pristine C60
fullerene was shown in vitro on diﬀerent cell lines, including human
keratinocytes HaCaT and human lung carcinoma cells A549 [39],
human monocyte-derived macrophage cells [40], mouse macrophages
RAW 264.7 [41], human mammary epithelial cells MCF10A and MDA
MB 231 [42]. Though the intracellular accumulation of nanostructures
was proved, still little is known about its subcellular localization, as
well as its ability to relocate and to realize eﬀects at the level of in-
tracellular compartments in cells of diﬀerent types.
3.2. Qualitative analysis
The intracellular uptake and distribution of C60 fullerene was stu-
died by ﬂuorescent immunostaining of human leukemic CCRF-CEM
cells using a FITC-labeled antibody against C60. DNA-binding dye DAPI
was used as a cell nucleus marker and MitoTracker Orange as a mi-
tochondrial marker. No signiﬁcant unspeciﬁc green FITC-ﬂuorescence
was observed in the control cells incubated in the absence of C60 full-
erene. On Fig. 2B the images of CCRF-CEM cells stained after 24 h in-
cubation with C60 are presented. No changes in nucleus ﬂuorescence as
compared with controls were found, whereas green ﬂuorescent punc-
tuated dots surrounding the nucleus were detected (Fig. 2B). The data
showed that C60 fullerene could diﬀuse through the cell plasma mem-
brane and locate in the perinuclear region of leukemic cells. Next, we
have evaluated whether C60 fullerene could localize in the mitochon-
dria membranes. The data of ﬂuorescent microscopy veriﬁed a partial
co-localization of C60 antibodies and the mitochondrial marker. The
intensity proﬁles of the three ﬂuorescence channels (Fig. 2C) for in-
dividual cells (Fig. 2A, B arrows) revealed the overlap of the green C60
fullerene and the red mitochondria signals. These data support the
evidence of C60 fullerene localization in mitochondria of human leu-
kemic cells.
3.3. Quantitative analysis
To study the accumulation dynamics we have extracted C60 full-
erene from the cell homogenate as well as from the mitochondrial
fraction and carried out liquid chromatography mass-spectrometry
analysis. This method together with electro-spray ionization was pre-
viously reported to be an eﬀective tool for C60 fullerene quantiﬁcation
in water samples [43], zebraﬁsh embryo [44] and human skin kerati-
nocytes HaCaT [25]. The method [35] enabled the quantitative analysis
of C60 fullerene accumulation in CCRF-CEM cells. According to the data
presented on Fig. 2D the intracellular content of C60 fullerene reached
its maximum of< 250 ng/106cells after 24 h of incubation. A sub-
sequent minor decrease of C60 fullerene content in leukemic cells ex-
tract at 48 h could be accounted by its partial eﬄux from the cancer
cells.
HPLC-ESI-MS analysis of C60 fullerene content in the mitochondria
fraction showed accumulation of the nanostructure at a level of<
180 ng/106 cells at 24 h that amounted to 72% of its overall content in
cell extract. This data demonstrate that C60 fullerene predominantly
accumulates within mitochondria. This could be explained by a high
electronegativity of C60 fullerene and a resulting aﬃnity to the mi-
tochondria-associated proton pool [22,45]. According to density func-
tional theory simulations, C60 fullerene diﬀuses into the protonated
mitochondrial intermembrane space, where it interacts with up to 6
protons, acquiring a positive charge [34]. This phenomenon is common
for other negatively charged carbon nanoparticles such as single walled
carbon nanotubes [46,47]. These were shown to be localized in mi-
tochondria of diﬀerent cells, too (ASTC-a-1, MCF 7, COS 7, EVC304 and
RAW264.7) [48].
3.4. LED-assisted photodynamic therapy in vitro
Photosensitizing eﬀects of C60 fullerene and its derivatives are in-
duced by diﬀerent visible light sources including broadband mercury-
vapor [11,27,31], halogen [2,19,49,50], tungsten-xenon [51,52] and
ﬂuorescent [53] lamps as well as sharp band lasers [2,16,53]. A recent
study [54] demonstrates C60 fullerene photoinduced cytotoxic eﬀects
against leukemic cells after irradiation with the white light-emitting
diode lamp with the board emission spectrum (420–700 nm). LEDs as a
light-source for PDT have been explored previously and were shown to
be more cost-eﬀective and serviceable as clinical lamps or lasers
[32–34]. The fractionation of light is a promising tool for the optimi-
zation of PDT in order to select the most eﬀective combination of the
photosensitizing agent and the light conditions such as light wavelength
and ﬂuence [1,51], that can be realized with the use of sharp spectrum
LEDs. In this study we tested four high output light-emitting diode chips
with 365, 405, 515 and 650 nm light irradiation.
The eﬃciency of light-induced excitation of photosensitizing agents
substantially depends on their relative optical absorption extinction
coeﬃcients. The UV/Vis absorption spectrum (200–900 nm) of pristine
C60 fullerene aqueous colloidal solution (Fig. 3A) has three intense
absorption bands typical for C60 [28] with maxima at 220, 265, and
350 nm and a long broad tail up to the red region of the visible light.
Fig. 3A demonstrates that the absorption spectrum of C60 fullerene and
the spectra of the used LEDs are overlapping, suggesting that they could
be applied for C60 photoexcitation.
After 24 h treatment with C60 fullerene leukemic cells were irra-
diated and at 48 h the cell viability was estimated with the MTT assay.
As shown in Fig. 3B-D, the eﬀect of light irradiation itself on CCRF-CEM
cell viability depends on light wavelength. Irradiation of cells in the
ultraviolet light at 365 nm was followed by decrease of cell viability.
The eﬀect became stronger with the increase of the light ﬂuence. After
irradiation with 8 J/cm2 the viability was only 32% compared to via-
bility of control cells in the dark. So the high toxic eﬀects of UV light
itself makes its application unfavorable. Irradiation with visible light
was followed by less cytotoxic eﬀect in comparison with UV irradiation
even considering the fact, that the visible light was used at higher
ﬂuences. After irradiation with violet light at 405 nm at a maximal dose
(20 J/cm2) cell viability was decreased on 16% of the control level
(Fig. 3C). Light irradiation at 405 nm is used in practice for the ster-
ilization of both clinical and nonclinical environment due to the strong
bactericidal activity [55,56], but its inactivating eﬀect against mam-
malian cells is slight [55,57]. No signiﬁcant toxic eﬀect was observed
after cells irradiation with green light at 515 nm and red light at 650 nm
with ﬂuence rate of 20 J/cm2, the cell viability was 90% and 95% ac-
cordingly as compared with control (Fig. 3D and Fig. SI 1).
We next studied cell viability after treatment with C60 fullerene and
photoexcitation of accumulated nanostructures. No cytotoxic eﬀect was
detected when CCRF-CEM cells were treated with C60 and kept in the
dark. When cells were incubated for 24 h in the presence of 20 µM C60
fullerene and then irradiated with 365 nm or 405 nm LEDs, a sub-
stantial decrease of cell viability was observed at 24 h after light ex-
posure (Fig. 3B and C). Сombined treatment with C60 fullerene and UV
365 nm light at the doses of 2 and 4 J/cm2 decreased cell viability up to
39% and 7% respectively as compared with control cells. The increase
of UV LED light ﬂuence up to 8 J/cm2 was followed by almost total cell
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Fig. 2. Intracellular uptake and localization of C60 fullerene in CCRF-CEM cells. Fluorescence microscopy images of CCRF-CEM cells, stained with DAPI (blue),
MitoTrecker (red) and FITC-labeled antibody against C60 fullerene (green): A – control cells, B – cells incubated for 24 h in the presence of 20 µM C60 fullerene, Scale
bar 20 µm; C – Linear ﬂuorescence proﬁles of single cell along the yellow arrows, indicated on the Merge images: 1, 2 – control cells, 3, 4 – cells incubated for 24 h in
the presence of 20 µM C60, D – HPLC-ESI-MS analysis of C60 fullerene content in cell extract and mitochondrial fraction after 0–48 h incubation of cells in presence of
20 µM C60 fullerene.
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death (Fig. 3B). Photoexcitation of accumulated C60 fullerene with
violet 405 nm light at 5, 10 and 20 J/cm2 light ﬂuence caused cell
viability decrease by 73%, 54% and 10%, respectively, as compared
with control cells (Fig. 3C). C60 fullerene exhibited lower cytotoxicity
under green 515 nm LED light irradiation. The viability of cells, treated
with C60 fullerene for 24 h and exposed to the 5 and 10 J/cm2 green
LED light irradiation, was estimated to be around 85% with a further
10% decrease at 20 J/cm2 (Fig. 3D). No fullerene cytotoxicity was ob-
served at the further shift of the light wavelength into the red region of
visible spectrum (Fig. SI 1). No signiﬁcant eﬀect on the viability of
leukemic cells, incubated either in the presence or the absence of 20 µM
C60 fullerene was detected under 650 nm LED light irradiation. Even
Fig. 3. In vitro C60 fullerene photodynamic therapy of human leukemic cells. A – Absorption spectrum of C60 fullerene and spectra of 365, 405, 515 and 650 nm LEDs;
Viability of CCRF-CEM cells, incubated for 24 h in absence or presence of 20 µM C60 fullerene and irradiated with 365 (B), 405 (C) and 515 (D) nm LEDs at diﬀerent
light ﬂuence.
Fig. 4. Reactive oxygen species generation in CCRF-CEM cells (A) and ﬂuorescent microscopy images (B) at 1 h and 3 h after treatment with either C60 fullerene or
irradiation at 405 nm 10 J/cm2 alone or their combination, Scale bar 20 µm.
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when we have applied intensities up to 80 J/cm2 with the use of 650 nm
helium-neon 30mW laser no cytotoxic eﬀect was observed because of
low absorbance of longwavelength light by C60. In order to increase the
red light absorbance C60 fullerene can be modiﬁed with decacationic
radicals [51] and additional red light harvesting chromophores [21,58]
or excited with simultaneously delivered two near-infrared photons
[2,59].
The anticancer eﬀect of pristine C60 fullerene and LEDs light irra-
diation combination against human leukemic cells was shown to be
strongly dependent on the light wavelength and ﬂuence. The short-
wavelength LEDs light irradiation was followed by most substantial
decrease of leukemic cells viability, loaded with C60 fullerene. The ef-
ﬁciency of combined eﬀect of C60 fullerene and LEDs light irradiation
was proved to follow an expected order 365 nm > 405 nm> 515
nm > 650 nm (no eﬀect). The obtained results indicate, that high
output single chip 405 nm LED is the most favorable light source for C60
fullerene photodynamic therapy of human leukemic cells at intensities
from 5 to 20 J/cm2. The application of a 405 nm sharp spectrum high
output LED chip for C60 fullerene photodynamic therapy allows to de-
crease the light dose in comparison with broad spectrum light sources,
that are used at higher ﬂuence rates of more than 100 J/cm2
[2,26,50,60].
3.5. Reactive oxygen species generation
The eﬃcient and continuous intracellular ROS production is a cri-
tical step for realization of a photoexcited C60 fullerene anticancer ef-
fect. ROS generation was estimated with the use of the ﬂuorescence dye
2′,7′-dichlorodihydroﬂuorescein diacetate [61,62]. DCFH-DA is able to
penetrate inside the cell, where it is deacyleted by esterases to its non-
ﬂuorescent form DCFH. Upon interaction with intracellular ROS DCFH
is oxidized to DCF, which is characterized by a high green ﬂuorescence.
DCFH is mostly sensitive to hydroxyl radical, peroxonitrite and H2O2
[62]. CCRF-CEM cells, treated with 10 and 20 µM C60 fullerene were
irradiated at 10 J/cm2 405 nm. The ROS production was studied after 1
and 3 h of light exposure respectively. When DCFH-DA was added to
untreated cells the slight continuous increase of ﬂuorescence intensity
was detected (Fig. 4A). Neither C60 fullerene nor light exposure alone
caused signiﬁcant changes in ROS generation in comparison with
control, while at combined treatment with C60 fullerene and 405 nm
LED light, ROS production in CCRF-CEM cells was shown to be in-
creased dramatically. Irradiation of cells treated with 10 µM C60 was
followed by 4-fold while treated with 20 µM C60 – by 8- and 10-fold
increase of ROS level at 1 and 3 h respectively (Fig. 4A). The micro-
scopy analysis of cells, presented on Fig. 4B, conﬁrmed DCF ﬂuorescent
measurement data, thus, indicating that photoexcitation of accumu-
lated C60 fullerene with 405 nm LED was followed by oxidative stress in
Fig. 5. Induction of apoptosis by C60 fullerene irradiation. A – Caspase 3/7 activity in CCRF-CEM cells, B – FACS histograms of CCRF-CEM cells, stained with Annexin
V-FITC/PI (in each panel the lower left quadrant shows the content of viable, upper left quadrant – early apoptotic, upper right quadrant – late apoptotic, lower right
quadrant – necrotic cells populations), C – Quantitative analysis of cell populations content, diﬀerentiated with double Annexin-FITC/PI staining after treatment of
CCRF-CEM cells either with C60 fullerene alone or in combination with 405 nm light.




The photosensitizing potential of intracellular accumulated C60
fullerene irradiated with 405 nm LED light was further studied by
evaluation of the caspase 3/7 activity and plasma membrane phos-
phatidylserine translocation as primary markers of cell death by
apoptosis. CCRF-CEM cells were incubated for 24 h in the presence or
absence of C60 fullerene, irradiated with 405 nm LED and caspase 3/7
activity was measured during further 6 h incubation. We have shown
that light irradiation alone had no eﬀect on caspase 3/7 activity, while
C60 fullerene photoexcitation was followed by 4-fold increase of caspase
3/7 activity at 3 h in comparison with control (Fig. 5A).
Exposure of phosphatidylserine on cell surface is proved to be an
“eat me” signal, which facilitates phagocytic recognition of apoptotic
cells and their destruction [63]. CCRF-CEM cells, treated with C60 and
either kept in the dark or irradiated with 405 nm LED, were subjected to
double staining with phosphatidylserine-binding Annexin V-FITC and
DNA-binding dye propidium iodide. On FACS histograms (Fig. 5B) four
populations of cells are presented according to green (annexin V-FITC)
and red (PI) ﬂuorescence intensities: viable (annexin V-FITC negative,
PI negative), early apoptotic (annexin V-FITC positive, PI negative), late
apoptotic (annexin V-FITC positive, PI positive) and necrotic (annexin
V-FITC negative, PI positive) cells. Quantitative analysis of cell popu-
lations content at 6 and 24 h after combined treatment of CCRF-CEM
cells with C60 and 405 nm light is presented on Fig. 5C. Neither treat-
ment with 20 µM C60 nor 405 nm light irradiation alone had signiﬁcant
eﬀect on cells distribution proﬁles, demonstrating a viability rate
around 95%. Under combined action of C60 fullerene and 405 nm light
a time-dependent increase in the content of apoptotic CCRF-CEM cells
was detected, that reached level of 18% and 50% at 6 and 24 h after
light exposure respectively, compared to 4% of control cells, treated
with C60 fullerene and kept in the dark (Fig. 5B, C). The obtained data
allow to conclude that toxic eﬀect of C60 fullerene against CCRF-CEM
cells after photoexcitation is realized by apoptosis induction.
4. Conclusions
With the use of immunocytochemical staining and mass spectro-
metry we have shown that pristine C60 fullerene was taken up by
human leukemic CCRF-CEM cells from the media in a time-dependent
manner, reaching a maximum intracellular level of almost 250 ng/106
cells at 24 h of incubation and was predominantly localized within
mitochondria. The comparative analysis of a potential phototoxicity of
C60 fullerene in human leukemic cells using LEDs of diﬀerent wave-
lengths revealed that the most favorable eﬀect was at 405 nm, 10 J/
cm2. No C60 fullerene neither 405 nm LED light alone impaired cell
viability, while their combined action was followed by 46% cell via-
bility decrease, 10-fold increase of reactive oxygen species generation,
4-fold increase of apoptosis-executive caspases 3/7 activity and plasma
membrane phosphatidylserine externalization in 50% of cells. Our data
suggest the use of C60 fullerene and 405 nm high power LED as a light
source for photodynamic treatment of cancer cells.
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